Open AccessPersonalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement
Author(s) -
Şuayib Yalçın,
Diaeddine Trad,
Yasser Abdel Kader,
H. Halawani,
Osman Demir,
Riaz Mall,
Andrey Meshcheryakov,
Fadi Nasr,
A. Nosworthy,
Dmitry Osinsky,
Assel Tumanova,
Serdar Turhal,
Sabine Tejpar,
ClausHenning Köhne
Publication year - 2014
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon.14.203
Subject(s) - medicine , bevacizumab , panitumumab , cetuximab , oncology , colorectal cancer , targeted therapy , chemotherapy , cancer
ABSTRACT The VEGF- (bevacizumab) and EGFR- (cetuximab and panitumumab) targeting monoclonal antibodies have become integral components of the first-line treatment strategies for patients with metastatic colorectal cancer (mCRC). Increasingly combination chemotherapy, with or without a targeted agent, is being used to facilitate curative liver resection and improve survival rates in patients with initially unresectable but potentially resectable mCRC. Currently, the only selective marker for the treatment of patients with mCRC is tumor RAS mutational status. BRAF status is a strong prognostic indicator. Medical and clinical oncologists from Central Asia, Russia, the Middle East, Africa and Turkey reviewed data for the use of targeted agents in the treatment of patients with mCRC and have formed recommendations for the biological of choice first-line for patients with mCRC.